A team from the Medicines Control Agency (MCA), The Gambia, is currently on a study visit to the Senegalese Pharmaceutical Regulatory Agency (ARP) from 28 July to 1 August 2025. This visit forms part of ongoing efforts to strengthen collaboration between the two National Regulatory Authorities (NRAs) on their Regulatory Functions including the fight against Substandard and Falsified Medical Products (SFMPs) in ensuring the availability of quality, safe and efficacious medical products across Senegal and The Gambia (Senegambia).
A significant highlight of the visit was the signing of a Memorandum of Understanding (MoU) between MCA and ARP on 28 July 2025. The MoU provides an important platform for MCA to learn from ARP’s experiences on its journey towards achieving WHO Maturity Level 3. This marks a milestone in the regulation of medical products in both countries, especially considering porous borders between the two countries.